2025 Mar 14, 14:12
Elpiscience Biopharma and Astellas Pharma have formed a research collaboration and licensing agreement to develop novel bi-specific macrophage engagers, including the compounds ES019 and another program. The two companies will work together on early-stage research for these two programs. As part of the agreement, Elpiscience will grant Astellas the right to add up to two additional programs to the collaboration. In return, Elpiscience will receive a total of $37 million, which includes upfront payment and license option fees
If Astellas exercises its option, Elpiscience may be eligible for over $1.7 billion in payments for future development, regulatory, and commercial milestones. This collaboration highlights the commitment of both companies to advancing scientific research and developing innovative treatments. The partnership brings together the expertise of Elpiscience in biopharmaceuticals and the resources of Astellas in clinical development and commercialization. By combining forces, the two companies hope to accelerate the discovery and development of potential therapies for patients in need
This collaboration represents a significant step forward in advancing the field of bi-specific macrophage engagers, which have shown promise in targeting multiple disease pathways. The partnership also highlights the growing interest in immuno-oncology and the potential of macrophage-based therapies. Both Elpiscience and Astellas are excited about the prospects of this collaboration and look forward to working together to bring innovative treatments to patients. The agreement underscores the shared commitment of both companies to improving patient outcomes and addressing unmet medical needs
With their combined expertise and resources, Elpiscience and Astellas are well-positioned to unlock the full potential of bi-specific macrophage engagers and make a meaningful impact in the field of oncology. This collaboration marks an important milestone for both companies and represents a significant opportunity for scientific advancement and therapeutic innovation. Through this partnership, Elpiscience and Astellas aim to push the boundaries of biotechnology and make groundbreaking discoveries that have the potential to transform patient care.